Nektar Therapeutics (NKTR) News Today $1.00 -0.03 (-2.91%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Nektar presents preclinical data on NKTR-422 at ACR conferenceNovember 20 at 6:34 AM | markets.businessinsider.comNektar Therapeutics Presents First Preclinical Data from Novel CSF-1 Program, NKTR-422, at 2024 American College of Rheumatology (ACR) ConvergenceNovember 18 at 3:30 PM | prnewswire.comMultiple Catalysts Ahead For Nektar TherapeuticsNovember 15, 2024 | seekingalpha.comDeep Track Capital, LP Reduces Stake in Nektar TherapeuticsNovember 14, 2024 | gurufocus.comNektar Therapeutics Reports Third Quarter 2024 Financial ResultsSAN FRANCISCO, November 7, 2024 - Nektar Therapeutics (Nasdaq: NKTR) recently disclosed its financial standing for the third quarter that concluded on September 30, 2024. The company's cNovember 11, 2024 | americanbankingnews.comNektar Therapeutics (NASDAQ:NKTR) Just Reported And Analysts Have Been Lifting Their Price TargetsNovember 10, 2024 | finance.yahoo.comNektar presents late-breaking results from Phase 2 Study of NKTR-255November 9, 2024 | markets.businessinsider.comNektar Therapeutics Reports Stable Q3 Earnings for 2024November 9, 2024 | markets.businessinsider.comNektar Therapeutics (NKTR) Q3 2024 Earnings Call Highlights: Strategic Moves and Financial OutlookNovember 9, 2024 | finance.yahoo.comQ3 2024 Nektar Therapeutics Earnings Call TranscriptNovember 8, 2024 | gurufocus.comNektar Therapeutics Reports Third Quarter 2024 Financial ResultsNovember 7, 2024 | prnewswire.comNektar and Collaborators Present Late-breaking Results from Phase 2 Study of NKTR-255 for the Treatment of Radiation Induced Lymphopenia in Locally Advanced Non-Small Cell Lung Cancer Patients at Society for Immunotherapy of Cancer (SITC) Annual MeetingNovember 7, 2024 | prnewswire.comNektar To Sell Manufacturing Facility In Alabama, Reagent Supply Business To AmpersandNovember 6, 2024 | markets.businessinsider.comNektar Therapeutics Q3 2024 Earnings PreviewNovember 6, 2024 | msn.comNektar Therapeutics to Participate in Upcoming Investor ConferencesNovember 6, 2024 | prnewswire.comNektar to sell its Huntsville, Alabama facility to Ampersand Capital for $90MNovember 5, 2024 | markets.businessinsider.comNektar Therapeutics to sell Alabama facility to AmpersandNovember 5, 2024 | finance.yahoo.comNektar Therapeutics Sells Manufacturing Facility for $90MNovember 5, 2024 | markets.businessinsider.comPiper Sandler Initiates Coverage of Nektar Therapeutics (NKTR) with Overweight RecommendationNovember 5, 2024 | msn.comEczema Drug Developer Nektar Gains Analyst Confidence With 400% Upside PotentialNovember 4, 2024 | benzinga.comNektar Announces Definitive Agreement with Ampersand Capital Partners to Sell Its Commercial PEGylation Reagent Manufacturing Business in AlabamaNovember 4, 2024 | prnewswire.comNektar Therapeutics (NASDAQ:NKTR) Now Covered by Piper SandlerPiper Sandler began coverage on shares of Nektar Therapeutics in a research note on Monday. They set an "overweight" rating and a $7.00 price target on the stock.November 4, 2024 | marketbeat.comNektar Therapeutics (NKTR) to Release Earnings on ThursdayNektar Therapeutics (NASDAQ:NKTR) will be releasing earnings after the market closes on Thursday, November 7, Zacks reports.November 1, 2024 | marketbeat.comNektar to Announce Financial Results for the Third Quarter 2024 on Thursday, November 7, 2024, After Close of U.S.-Based Financial MarketsOctober 31, 2024 | prnewswire.comNektar reports positive Phase 1b skin disease study resultsOctober 31, 2024 | investing.comNektar Therapeutics (NASDAQ:NKTR) Given Average Recommendation of "Hold" by BrokeragesShares of Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) have earned an average recommendation of "Hold" from the six ratings firms that are presently covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, two have given a hold recommendation andOctober 31, 2024 | marketbeat.comNektar Announces Publication in Nature Communications of Results from Phase 1b Studies of Rezpegaldesleukin in Two Inflammatory Skin DiseasesOctober 29, 2024 | prnewswire.comNektar Therapeutics (NASDAQ:NKTR) Short Interest UpdateNektar Therapeutics (NASDAQ:NKTR - Get Free Report) saw a significant drop in short interest during the month of October. As of October 15th, there was short interest totalling 6,040,000 shares, a drop of 17.4% from the September 30th total of 7,310,000 shares. Based on an average daily volume of 1,030,000 shares, the short-interest ratio is presently 5.9 days. Approximately 3.4% of the shares of the company are short sold.October 28, 2024 | marketbeat.comNektar Therapeutics (NASDAQ:NKTR) Stock Crosses Above Two Hundred Day Moving Average - What's Next?Nektar Therapeutics (NASDAQ:NKTR) Share Price Crosses Above Two Hundred Day Moving Average - Here's What HappenedOctober 22, 2024 | marketbeat.comNektar sees promising phase 1 results of NKTR-255 in B-cell lymphoblastic leukemiaOctober 17, 2024 | msn.comNektar Announces Publication in Blood of Phase 1 Data for Novel IL-15 Agonist NKTR-255 in Combination with Autologous CD19-22 CAR-T Cell Therapy in Patients with B-cell Acute Lymphoblastic LeukemiaOctober 17, 2024 | prnewswire.comMillennium Management LLC Acquires 1,674,924 Shares of Nektar Therapeutics (NASDAQ:NKTR)Millennium Management LLC raised its holdings in shares of Nektar Therapeutics (NASDAQ:NKTR - Free Report) by 56.1% in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 4,659,469 shares of the biopharmaceutical company's stock after purOctober 12, 2024 | marketbeat.comNektar Therapeutics (NASDAQ:NKTR) Stock, Short Interest ReportOctober 10, 2024 | benzinga.comNektar Therapeutics (NASDAQ:NKTR) Receives Average Recommendation of "Hold" from BrokeragesShares of Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) have earned an average recommendation of "Hold" from the six ratings firms that are currently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, two have issued a hold rating andOctober 6, 2024 | marketbeat.comNantahala Capital Management LLC Has $5.10 Million Stake in Nektar Therapeutics (NASDAQ:NKTR)Nantahala Capital Management LLC grew its position in Nektar Therapeutics (NASDAQ:NKTR - Free Report) by 66.0% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,110,000 shares of the biopharmaceuticalOctober 1, 2024 | marketbeat.comBTIG Research Reiterates "Buy" Rating for Nektar Therapeutics (NASDAQ:NKTR)BTIG Research restated a "buy" rating and issued a $4.00 price target on shares of Nektar Therapeutics in a research note on Monday.September 30, 2024 | marketbeat.comRenaissance Technologies LLC Sells 1,306,848 Shares of Nektar Therapeutics (NASDAQ:NKTR)Renaissance Technologies LLC lowered its position in Nektar Therapeutics (NASDAQ:NKTR - Free Report) by 28.3% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,313,833 shares of the biophaSeptember 29, 2024 | marketbeat.com836,000 Shares in Nektar Therapeutics (NASDAQ:NKTR) Acquired by Armistice Capital LLCArmistice Capital LLC bought a new stake in shares of Nektar Therapeutics (NASDAQ:NKTR - Free Report) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 836,000 shares of the biopharmaceutical company's stock, valued at approximaSeptember 27, 2024 | marketbeat.comNektar Therapeutics Announces Multiple Presentations for Rezpegaldesleukin at EADV 2024September 25, 2024 | prnewswire.comSamlyn Capital LLC Makes New $11.73 Million Investment in Nektar Therapeutics (NASDAQ:NKTR)Samlyn Capital LLC bought a new position in shares of Nektar Therapeutics (NASDAQ:NKTR - Free Report) in the second quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 9,457,887 shares of the biopharmaceutical company's stock, valued at approSeptember 24, 2024 | marketbeat.comBank of New York Mellon Corp Grows Stock Position in Nektar Therapeutics (NASDAQ:NKTR)Bank of New York Mellon Corp increased its position in shares of Nektar Therapeutics (NASDAQ:NKTR - Free Report) by 2,822.5% in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 551,535 shares of the biopharmaceutical company's stock after purcSeptember 23, 2024 | marketbeat.comNektar Therapeutics (NASDAQ:NKTR) Shares Sold by Primecap Management Co. CAPrimecap Management Co. CA trimmed its position in Nektar Therapeutics (NASDAQ:NKTR - Free Report) by 13.6% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 6,020,453 shares of the biopharmaceutical company's stSeptember 19, 2024 | marketbeat.comAcadian Asset Management LLC Sells 2,684,469 Shares of Nektar Therapeutics (NASDAQ:NKTR)Acadian Asset Management LLC lessened its holdings in shares of Nektar Therapeutics (NASDAQ:NKTR - Free Report) by 35.5% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 4,884,594 shares of the biopharmaceutical company's sSeptember 12, 2024 | marketbeat.comNektar Therapeutics (NASDAQ:NKTR) Given Consensus Rating of "Hold" by BrokeragesNektar Therapeutics (NASDAQ:NKTR - Get Free Report) has been given an average rating of "Hold" by the five analysts that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating on the comSeptember 11, 2024 | marketbeat.comMonaco Asset Management SAM Lowers Position in Nektar Therapeutics (NASDAQ:NKTR)Monaco Asset Management SAM decreased its stake in shares of Nektar Therapeutics (NASDAQ:NKTR - Free Report) by 62.8% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 2,166,432 shares of the biopharmaceuticaSeptember 10, 2024 | marketbeat.comNektar Management to Present at Upcoming Investor ConferencesSeptember 3, 2024 | prnewswire.comNektar Therapeutics (NASDAQ:NKTR) Stock Quotes, Forecast and News SummaryAugust 27, 2024 | benzinga.comNektar Therapeutics (NASDAQ:NKTR) CEO Howard W. Robin Sells 14,881 SharesAugust 21, 2024 | insidertrades.comHoward W. Robin Sells 14,881 Shares of Nektar Therapeutics (NASDAQ:NKTR) StockNektar Therapeutics (NASDAQ:NKTR - Get Free Report) CEO Howard W. Robin sold 14,881 shares of the company's stock in a transaction that occurred on Monday, August 19th. The shares were sold at an average price of $1.28, for a total value of $19,047.68. Following the completion of the transaction, the chief executive officer now directly owns 848,358 shares of the company's stock, valued at approximately $1,085,898.24. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.August 20, 2024 | marketbeat.comNektar Therapeutics (NASDAQ:NKTR) Given Consensus Rating of "Hold" by AnalystsShares of Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) have earned an average recommendation of "Hold" from the five research firms that are presently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, two have assigned a hold recoAugust 17, 2024 | marketbeat.com Get Nektar Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NKTR and its competitors with MarketBeat's FREE daily newsletter. Email Address Urgent: This election is rigged (Ad)If you missed it, my emergency election broadcast is now available - but will be removed soon Click here to watch it now. NKTR Media Mentions By Week NKTR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NKTR News Sentiment▼0.000.45▲Average Medical News Sentiment NKTR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NKTR Articles This Week▼62▲NKTR Articles Average Week Get Nektar Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NKTR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ADCT News Today MCRB News Today AVIR News Today OMER News Today ASMB News Today CPIX News Today AGIO News Today ALKS News Today NVO News Today LLY News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NKTR) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nektar Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share Nektar Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
